Sarcopenia Market

Market Overview:

The 7 major sarcopenia markets reached a value of US$ 1.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.3 Billion by 2034, exhibiting a growth rate (CAGR) of 4.1% during 2024-2034.

The sarcopenia market has been comprehensively analyzed in IMARC's new report titled "Sarcopenia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Sarcopenia refers to a medical condition characterized by the progressive loss of muscle mass, strength, and function that occurs as a natural part of the aging process. It is often caused by a misalignment of signals for muscle cell growth and breakdown, resulting in reduced quality of life, fractures, falls, and disability. The most prominent symptom of sarcopenia is muscle weakness. Individuals suffering from this condition may also experience loss of stamina, difficulty performing daily activities, trouble climbing stairs, poor balance and falls, decrease in muscle size, etc. The diagnosis of the ailment is based on a review of the patient's clinical features, medical history, and physical exam. The healthcare professional may additionally perform muscle strength studies, including handgrip test, chair stand test, short physical performance battery, walking speed exam, timed-up and go test, etc. In some cases, a dual-energy X-ray absorptiometry (DEXA), which uses low-power X-rays to measure muscle mass, fat, and bone density, is also recommended to confirm a diagnosis.

The expanding geriatric population, who are more susceptible to changes in the number and size of muscle fibers, is primarily driving the sarcopenia market. In addition to this, the increasing incidences of several associated risk factors, including sedentary lifestyle, obesity, hormonal imbalance, inadequate protein intake, neurological disorders, etc., are further augmenting the market growth. Moreover, the emerging popularity of effective medications, such as β-hydroxy β-methyl butyrate, which acts as a signaling molecule to enhance protein synthesis and prevent loss of lean body mass, is also creating a positive outlook for the market. Apart from this, the widespread adoption of bioelectrical impedance analysis for diagnosing the disease owing to its numerous benefits, including minimal invasion, portability, ease of use, relatively low cost, safety, etc., is further bolstering the market growth. Additionally, the escalating utilization of resistance and strength training to treat the condition by increasing muscle protein synthesis and supporting muscular strength is acting as another significant growth-inducing factor. Besides this, the rising usage of myostatin inhibitors that can promote healthy muscle mass and improve mobility in patients is expected to drive the sarcopenia market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the sarcopenia market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for sarcopenia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the sarcopenia market in any manner.

Recent Developments:

• In March 2024, Biophytis presented its phase 3 protocol to demonstrate the potential of Ruvembri (20-hydroxyecdysone) in the treatment of sarcopenia. Based on the results of the SARA-INT phase 2 study, as well as the SPRINTT and LIFE investigations, the company planned an interventional, randomized, double-blind, placebo-controlled clinical phase 3 study (the SARA-31 study), which was intended to enroll 932 patients.
• In October 2023, MyMD Pharmaceuticals, Inc announced positive Phase 2 study outcomes in participants with sarcopenia/frailty. MYMD-1 demonstrated statistical significance in reducing serum levels of TNF-α, IL-6, and sTNFR1, biomarkers common to a number of chronic inflammatory diseases. The treatment met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days.
• In May 2023, Oncocross announced the conclusion of the phase 1 worldwide clinical study of OC514, a therapy that targets sarcopenia. The study was a randomized, double-blind, dose-ranging, placebo-controlled trial to assess the safety, pharmacodynamics, and pharmacokinetic effects of OC514 in 28 healthy volunteers.

Key Highlights:

• Sarcopenia is anticipated to affect 6–22% of the senior population (≥60 years), which is projected to double from 962 million in 2017 to 2.1 billion by 2050.
• According to a new study published in the international journal Elsevier, sarcopenia is increasingly recognized as a serious problem among younger people with type 2 diabetes.
• Sarcopenia rates ranged from 18% in diabetic people to 66% in patients suffering from unresectable esophageal cancer.
• Sarcopenia affects 44.8% of men and 30.24% of women.
• In Europe and the United States, the frequency of sarcopenia with different diagnostic criteria ranged from 4.6% to 43% in communities and from 23% to 68% in clinical settings.

Drugs:

MYMD-1 is an oral, next-generation TNF-α inhibitor that has the potential to revolutionize the treatment of TNF-α-based disorders because of its blood brain barrier-crossing capabilities and selectivity. The convenience of oral dosage distinguishes it from other TNF-α inhibitors that need injections or infusions. MYMD-1 has been demonstrated to specifically suppress TNF-α action when overactivated, without affecting its usual response to regular infections.

BIO101 (20-hydroxyecdysone) is an orally given small molecule being developed for the treatment of neuromuscular illnesses, including sarcopenia. The drug is a MAS receptor activator, which can demonstrate metabolic effects on muscle and fat tissues, thereby improving mobility and muscle strength in obese sarcopenic patients.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the sarcopenia market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the sarcopenia market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current sarcopenia marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the sarcopenia market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the sarcopenia market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the sarcopenia market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of sarcopenia across the seven major markets?
• What is the number of prevalent cases (2018-2034) of sarcopenia by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of sarcopenia by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with sarcopenia across the seven major markets?
• What is the size of the sarcopenia patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of sarcopenia?
• What will be the growth rate of patients across the seven major markets?
   

Sarcopenia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for sarcopenia drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the sarcopenia market?
• What are the key regulatory events related to the sarcopenia market?
• What is the structure of clinical trial landscape by status related to the sarcopenia market?
• What is the structure of clinical trial landscape by phase related to the sarcopenia market?
• What is the structure of clinical trial landscape by route of administration related to the sarcopenia market?